Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for Unicycive Therapeutics and Rapport Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Rapport Therapeutics | 1 | 0 | 10 | 2 | 3.00 |
Volatility and Risk
Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Earnings & Valuation
This table compares Unicycive Therapeutics and Rapport Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 218.70 | -$26.56 million | ($1.75) | -3.05 |
| Rapport Therapeutics | N/A | N/A | -$111.48 million | ($3.04) | -16.23 |
Unicycive Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Unicycive Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
| Rapport Therapeutics | N/A | -29.02% | -27.37% |
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
